tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2016 May 6:1-10. [Epub ahead of print]
[h=1]The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic.[/h] Chuaychoo B[SUP]1[/SUP], Kositanont U[SUP]2[/SUP], Rittayamai N[SUP]1[/SUP], Niyomthong P[SUP]1[/SUP], Songserm T[SUP]3[/SUP], Maranetra KN[SUP]1[/SUP], Rattanasaengloet K[SUP]1[/SUP], Nana A[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The antibody responses of a reduced-dose intradermal seasonal influenza vaccination have never been studied in COPD patients soon after a pandemic. A total of 149 COPD patients (60 y of age or older) were randomized to receive trivalent influenza vaccine (Sanofi-Pasteur, France) either 9 ?g of hemagglutinin (HA) per strain split into 2-site intradermal (ID) injections via the Mantoux technique or one intramuscular (IM) injection of 15 ?g of HA per strain. The geometric mean titers, seroconversion factors, seroconversion rates and seroprotection rates for influenza A(H3N2) and B administered through the ID injection (n = 75) were similar to those obtained with the IM injection (n = 74) 4 weeks post-vaccination. The antibody responses for influenza A(H1N1)pdm09 administered through the ID injection were lower than those obtained with the IM injection, but all of these responses met the 3 criteria proposed by the Committee for Proprietary Medicinal Products (CPMP) for annual re-licensure. The seroprotection rates 4 weeks post-vaccination for influenza A(H1N1)pdm09 were 64.0% (95%CI 52.7-74.0%) in the ID group vs. 78.4% (95% CI 67.6-86.3%) in the IM group (p = 0.053). Influenza-related acute respiratory illness (ARI), diagnosed as a 4-fold rise in HI titers with a convalescent titer > 1:40, and/or the RT-PCR between the ID group (5.3%) and the IM group (8.1%) were not significantly different. The reduced-dose intradermal influenza vaccine may expand vaccine coverage in cases of vaccine shortage.
[h=4]KEYWORDS:[/h] COPD; acute respiratory illness; immunogenicity; influenza A(H1N1)pdm09; influenza vaccine; intradermal
PMID: 27153158 [PubMed - as supplied by publisher]
[h=1]The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic.[/h] Chuaychoo B[SUP]1[/SUP], Kositanont U[SUP]2[/SUP], Rittayamai N[SUP]1[/SUP], Niyomthong P[SUP]1[/SUP], Songserm T[SUP]3[/SUP], Maranetra KN[SUP]1[/SUP], Rattanasaengloet K[SUP]1[/SUP], Nana A[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The antibody responses of a reduced-dose intradermal seasonal influenza vaccination have never been studied in COPD patients soon after a pandemic. A total of 149 COPD patients (60 y of age or older) were randomized to receive trivalent influenza vaccine (Sanofi-Pasteur, France) either 9 ?g of hemagglutinin (HA) per strain split into 2-site intradermal (ID) injections via the Mantoux technique or one intramuscular (IM) injection of 15 ?g of HA per strain. The geometric mean titers, seroconversion factors, seroconversion rates and seroprotection rates for influenza A(H3N2) and B administered through the ID injection (n = 75) were similar to those obtained with the IM injection (n = 74) 4 weeks post-vaccination. The antibody responses for influenza A(H1N1)pdm09 administered through the ID injection were lower than those obtained with the IM injection, but all of these responses met the 3 criteria proposed by the Committee for Proprietary Medicinal Products (CPMP) for annual re-licensure. The seroprotection rates 4 weeks post-vaccination for influenza A(H1N1)pdm09 were 64.0% (95%CI 52.7-74.0%) in the ID group vs. 78.4% (95% CI 67.6-86.3%) in the IM group (p = 0.053). Influenza-related acute respiratory illness (ARI), diagnosed as a 4-fold rise in HI titers with a convalescent titer > 1:40, and/or the RT-PCR between the ID group (5.3%) and the IM group (8.1%) were not significantly different. The reduced-dose intradermal influenza vaccine may expand vaccine coverage in cases of vaccine shortage.
[h=4]KEYWORDS:[/h] COPD; acute respiratory illness; immunogenicity; influenza A(H1N1)pdm09; influenza vaccine; intradermal
PMID: 27153158 [PubMed - as supplied by publisher]